مقاله انگلیسی بیماری پیشرفته مرتبط با واکسن
ترجمه نشده

مقاله انگلیسی بیماری پیشرفته مرتبط با واکسن

عنوان فارسی مقاله: بیماری پیشرفته مرتبط با واکسن: تعریف مورد و راهنمایی جهت جمع آوری داده ها، تحلیل و ارائه داده های ایمن سازی امن
عنوان انگلیسی مقاله: Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
مجله/کنفرانس: واکسن - Vaccine
رشته های تحصیلی مرتبط: پزشکی
گرایش های تحصیلی مرتبط: ایمنی شناسی پزشکی یا ایمونولوژی
کلمات کلیدی فارسی: رویداد معکوس، ایمن سازی، راهنمایی ها، تعریف مورد، واکسن، بیماری پیشرفته، تنفسی، بیماری سیستماتیک
کلمات کلیدی انگلیسی: Adverse event, Immunization, Guidelines, Case definition, Vaccine, Enhanced disease, Respiratory, Systemic disease
نوع نگارش مقاله: مقاله مروری (Review Article)
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.vaccine.2021.01.055
دانشگاه: Baylor College of Medicine, Houston, TX, USA
صفحات مقاله انگلیسی: 14
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2021
ایمپکت فاکتور: 3.274 در سال 2020
شاخص H_index: 184 در سال 2021
شاخص SJR: 1.585 در سال 2020
شناسه ISSN: 0264-410X
شاخص Quartile (چارک): Q1 در سال 2020
فرمت مقاله انگلیسی: PDF
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
آیا این مقاله فرضیه دارد: ندارد
کد محصول: E15523
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
نوع رفرنس دهی: vancouver
فهرست مطالب (انگلیسی)

Abstract

Keywords

1. Preamble

2. Rationale for selected decisions about the case definition of vaed/vaerd as an adverse event following immunization

3. Case definition of vaccine associated enhanced disease (VAED)

Declaration of Competing Interest

Acknowledgements

Disclaimer

Appendix A. Supplementary material

References

بخشی از مقاله (انگلیسی)

Abstract

This is a Brighton Collaboration Case Definition of the term “Vaccine Associated Enhanced Disease” to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission.

 

1. Preamble

Vaccine-associated enhanced diseases (VAED) are modified presentations of clinical infections affecting individuals exposed to a wild-type pathogen after having received a prior vaccination for the same pathogen [1]. Vaccine-associated enhanced respiratory (VAERD) disease refers to disease with predominant involvement of the lower respiratory tract. Classic examples of VAED are atypical measles and enhanced respiratory syncytial virus (RSV) occurring after administration of inactivated vaccine for these pathogens. In this situation, severe disease has been documented resulting from infection in individuals primed with non-protective immune responses against the respective wild-type viruses [2], [3], [4], [5], [6]. Given that these enhanced responses are triggered by failed attempts to control the infecting virus, VAED typically presents with symptoms related to the target organ of the infection pathogen. In order to recognize vaccine associated disease enhancement, it is therefore necessary to have a clear understanding of the clinical presentation and usual course of the natural disease.

Disease enhancement independent of vaccine priming has also been described for pathogens causing sequential infections with different cross-reactive but not cross-protective serotypes, including dengue and pandemic influenza [7], [8], [9], [10], [11], [12].

In late 2019, a novel severe respiratory illness emerged in Wuhan, China [13]. The causative agent, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), was promptly identified, and determined to be closely related to SARS and the Middle East Respiratory Syndrome (MERS) coronaviruses, which had caused geographically localized outbreaks in 2002–2004 and from 2012 onwards, respectively. SARS-CoV-2 progressed to a global pandemic with substantial consequences due to its high infectivity and transmissibility, and its ability to cause both a severe respiratory illness, and a systemic disease with fatal consequences for vulnerable populations. The natural history of coronavirus infectious disease caused by SARS-CoV-2 (COVID-19), is yet to be fully described. However, a case fatality rate that ranges from 0.5% to nearly 20% depending on age and other risk factors, and the understanding that SARS-CoV-2 is now a well-adapted human pathogen that will continue to cause disease in susceptible populations, makes the development of an effective vaccine a global priority.